Table 2 Comparison of the effect estimates on the desired outcomes between previous [12] and updated meta-analysis following addition of new studies for the selected early stage cervical cancer groups
From: Outcomes of ovarian transposition in cervical cancer; an updated meta-analysis
Outcome/type of therapy | New studies included in the updated meta-analysis (author & year of publication) | |||||
|---|---|---|---|---|---|---|
Surgery | Effect Estimate with 95% CI 2021 vs 2014 [12] | Surgery ± BR | Effect Estimate with 95% CI 2021 vs 2014 [12] | Surgery ± BR ± EBRT | Effect Estimate with 95% CI 2021 vs 2014 [12] | |
Preserved Ovarian Function | Du Z [33] 2017 | 0.91 (0.83 to 1.00) vs 0.91 (0.82 to 1.00) | None | No change | Du Z [33] 2017 Hoeckman [35] 2018 Lv [41] 2019 Shou [40] 2015 Swift [34] 2018 Yin L [42] 2019 | 0.61 (0.55 to 0.69) vs 0.62 (0.53 to 0.72) |
Metastases | Zhao [43] 2013 | 0.02 (0.01 to 0.05) vs 0.02 (0.00 to 0.08) | None | No change | None | No change |
Ovarian Cysts | None | No change | None | No change | Swift [34] 2018 | 0.16 (0.10 to 0.27) vs 0.16 (0.10 to 0.26) |